Why the study?
Copper promotes angiogenesis, but the mechanistic insights and the significance of copper-promoted angiogenesis in myocardial regeneration have not been fully elucidated until recently.
Targeted copper supplementation to ischemic myocardium represents a potential novel therapeutic approach to promote angiogenesis and myocardial regeneration.
Targeted copper delivery may promote post-ischemic regeneration; leaves open clinical efficacy pending prospective trials.
IMPACT STATEMENT: Copper promotes angiogenesis, but the mechanistic insights have not been fully elucidated until recently. In addition, the significance of copper promotion of angiogenesis in myocardial regeneration was increasingly revealed. Copper critically participates in the regulation of hypoxia-inducible factor 1 (HIF-1) of angiogenic gene expression. Interestingly, myocardial ischemia causes copper efflux from the heart, leading to suppression of angiogenesis, although HIF-1α, the critical subunit of HIF-1, remains accumulated in the ischemic myocardium. Strategies targeting copper specific delivery to the ischemic myocardium lead to selective activation of HIF-1-regulated angiogenic gene expression. Vascularization of the ischemic myocardium re-establishes the tissue injury microenvironment, and rebuilds the conduit for communication between the tissue injury signals and the remote regenerative responses including stem cells. This process promotes myocardial regeneration. Thus, a simple and effective copper supplementation to the ischemic myocardium would become a novel therapeutic approach to the treatment of patients with ischemic heart diseases.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: